CLINICAL TRIALS PROFILE FOR BELZUTIFAN
✉ Email this page to a colleague
All Clinical Trials for BELZUTIFAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02974738 ↗ | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | Active, not recruiting | Peloton Therapeutics, Inc. | Phase 1 | 2016-12-07 | The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors |
| NCT03401788 ↗ | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | Active, not recruiting | Peloton Therapeutics, Inc. | Phase 2 | 2018-05-02 | This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC. |
| NCT03445169 ↗ | A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets | Completed | Peloton Therapeutics, Inc. | Phase 1 | 2018-02-23 | This Phase 1, single-dose study will be conducted in adult male and female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria. This study will assess the effect of food on the pharmacokinetics of belzutifan Tablets. The study will consist of two periods and will be conducted in a crossover fashion. |
| NCT03634540 ↗ | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | Recruiting | Peloton Therapeutics, Inc. | Phase 2 | 2018-09-27 | This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily. |
| NCT04195750 ↗ | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | Recruiting | Merck Sharp & Dohme Corp. | Phase 3 | 2020-02-27 | The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS. |
| NCT04489771 ↗ | A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | Recruiting | Merck Sharp & Dohme Corp. | Phase 2 | 2020-09-13 | This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR). |
| NCT04586231 ↗ | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | Recruiting | Eisai Inc. | Phase 3 | 2021-02-25 | This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BELZUTIFAN
Condition Name
Clinical Trial Locations for BELZUTIFAN
Trials by Country
Clinical Trial Progress for BELZUTIFAN
Clinical Trial Phase
Clinical Trial Sponsors for BELZUTIFAN
Sponsor Name
